The DOI matches its Crossref record; 122 of the 123 references it cites were found in a registry or an index.
Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management
Open accessAbstract
Disease overview: Multiple myeloma is malignant plasma‐cell disorder that accounts for ∼∼10% of all hematologic malignancies. Diagnosis: The diagnosis requires (1) 10% or more clonal plasma cells on bone marrow examination or a biopsy‐proven plasmacytoma plus (2) evidence of end‐organ damage felt to be related to the underlying plasma cell disorder. Risk stratification: Patients with 17p deletion, t(4;14), t(14;16), t(14;20), and karyotypic deletion 13 or hypodiploidy are considered to have high‐risk myeloma. All others are considered to have standard‐risk disease. Risk‐adapted therapy: Standard‐risk patients are treated with nonalkylator‐based therapy such as lenalidomide plus low‐dose dexamethasone (Rd) followed by autologous stem‐cell transplantation (ASCT). If patients are tolerating the induction regimen treatment well, an alternative strategy is to continue initial therapy after stem‐cell collection, reserving ASCT for first relapse. High‐risk patients are treated with a bortezomib‐based induction followed by ASCT and then bortezomib‐based maintenance. Patients not eligible for ASCT can be treated with Rd for standard risk disease or a bortezomib‐based regimen if high‐risk features are present. To reduce toxicity, when using bortezomib, the once‐weekly dose is preferred; similarly, when using dexamethasone, the low‐dose approach (40 mg once a week) is preferred, unless there is a need for rapid disease control. Management of refractory disease: Patients with indolent relapse can be treated first with lenalidomide, bortezomib, or alkylators plus low‐dose corticosteroids. Patients with more aggressive relapse often require therapy with a combination of multiple active agents. The most promising new agents in development are pomalidomide and carfilizomib. Am. J. Hematol. 86:57–65, 2011. © 2010 Wiley‐Liss, Inc.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“KRd instead of VRd can be used as initial therapy in patients with t(4;14), t(14;16), t(14;20), and those with ≥2 high-risk abnormalities based on the results of phase 2 studies suggesting higher complete response (CR) rates and minimal residual disease negativity rates compared with historical results using VRd [28,30,31].”
From Epidemiology, Staging, and Management of Multiple Myeloma (2021) · cites this paper as [30]
Citations
Cites
1 retracted
Abdelkefi, A., Ladeb, S., Torjman, L., Othman, T. B., Lakhal, A., Romdhane, N. B., Omri, H. E., Elloumi, M., Bellâaj, H., Jeddi, R., et al. (2007) · Blood · doi:10.1182/blood-2007-07-101212 · Cited by 125
RetractedJemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
International Staging System for Multiple Myeloma
Greipp, P. R., Miguel, J. S., Durie, B. G. M., Crowley, J. J., Barlogie, B., Bladé, J., Boccadoro, M., Child, J. A., Avet-Loiseau, H., Kyle, R. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.242 · Cited by 2,974
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citationA Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Self-citationAntitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Richardson, P. G. G., Sonneveld, P., Schuster, M. W., Irwin, D. H., Stadtmauer, E. A., Facon, T. T. F., Harousseau, J., Ben‐Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043445 · Cited by 2,512
Review of 1027 Patients With Newly Diagnosed Multiple Myeloma
Kyle, R. A., Gertz, M. A., Witzig, T. E., Lust, J. A., Lacy, M. Q., Dispenzieri, A., Fonseca, R., Rajkumar, S. V., Offord, J. R., Larson, D. R., et al. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.1.21 · Cited by 2,447
Self-citationThe International Myeloma Working Group (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04355.x · Cited by 2,367
Research works printed but not linked: 10
- 10.4065/80.10.1371 · DOI
- 10.1016/S0025-6196(11)61029-X · DOI
- Jacobus S, 2010, Outcome of elderly patients 70 years and older with newly diagnosed myeloma in the ECOG randomized trial of lenalidomide/high‐dose dexamethasone (RD) versus lenalidomide/low‐dose dexamethasone (Rd), Haematologica, 95, 149
- Barlogie B, 2003, Comparable survival in multiple myeloma (MM) with high dose therapy (HDT) employing MEL 140 mg/m2 + TBI 12 Gy autotransplants versus standard dose therapy with VBMCP and no benefit from interferon (IFN) maintenance: Results of intergroup Trial S9321, Blood, 102, 42a
- Blade J, 2003, High‐dose therapy autotransplantation/intensification versus continued conventional chemotherapy in multiple myeloma patients responding to initial chemotherapy. Definitive results from PETHEMA after a median follow‐up of 66 months, Blood, 102, 42a
- Attal M, 2002, Double autologous transplantation improves survival of multiple myeloma patients: Final analysis of a Prospective Randomized Study of the “Intergroupe Francophone du Myelome” (IFM 94), Blood, 100, 5a
- Fermand JP, 2003, Single versus tandem high dose therapy (HDT) supported with autologous blood stem cell (ABSC) transplantation using unselected or CD34‐enriched ABSC: Results of a two by two designed randomized trial in 230 young patients with multiple myeloma (MM), Hematol J, 4, S59
- Goldschmidt H, 2003, Single vs. tandem autolgous transplantation in multiple myeloma: The GMMG experience, Hematol J, 4, S61
- Kumar S, 2010, Outcome of patients with myeloma relapsing after IMiD and bortezomib therapy: A multicenter study from the International Myeloma Foundation Working Group, Haematologica, 95
- Berenson JR, 2003, Experience with long‐term therapy using the proteasome inhibitor, bortezomib, in advanced multiple myeloma (MM), Proc Am Soc Clin Oncol, 22, 581
Cited by
Sorted by citations
Röllig, C., Knop, S. T., & Bornhäuser, M. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60493-1 · Cited by 626
Zavidij, O., Haradhvala, N. J., Mouhieddine, T. H., Sklavenitis-Pistofidis, R., Cai, S., Reidy, M., Rahmat, M., Flaifel, A., Ferland, B., Su, N. K., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0053-3 · Cited by 374
Epidemiology, Staging, and Management of Multiple Myeloma
Padala, S. A., Barsouk, A., Barsouk, A., Rawla, P., Vakiti, A., Kolhe, R., Kota, V., & Ajebo, G. H. (2021) · Medical Sciences · doi:10.3390/medsci9010003 · Cited by 332
Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology
Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L. D., Baljević, M., Campagnaro, E. L., Castillo, J. J., Chandler, J. C., Costello, C. L., Efebera, Y. A., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0057 · Cited by 283
Mateos, M., Blacklock, H. A., Schjesvold, F. H., Oriol, A., Simpson, D., George, A., Goldschmidt, H., Larocca, A., Chanan-Khan, A. A., Sherbenou, D. W., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30110-3 · Cited by 259
Metadata
- Authors
- Rajkumar, S. V.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Rajkumar, S. Vincent
- ORCID
- Rajkumar, S. Vincent
- Venue
- American Journal of Hematology
- Publisher
- Wiley
- Published
- 2010-12-22
- Volume
- 86
- Issue
- 1
- Pages
- 57-65
- ISSN
- 0361-8609 (ISSN-L)
- 1096-8652
- OpenAlex
- W2121283512
- Cited by
- 152
- References
- 123
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 4 · 2023: 2 · 2022: 7 · 2021: 6 · 2020: 4 · 2019: 10 · 2018: 3 · 2017: 9 · 2016: 7 · 2015: 10 · 2014: 20 · 2013: 23 · 2012: 24
- FWCI
- 3.28
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- American Journal of Hematology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Keywords
- multiple myeloma, diagnosis, risk stratification, high-risk myeloma, lenalidomide, bortezomib, autologous stem cell transplantation, maintenance therapy, relapsed multiple myeloma, low-dose dexamethasone, 17p deletion, plasmacytoma, pomalidomide
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Humans, Multiple Myeloma, Risk Factors, Survival Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
